13F Filings History of SENZAR ASSET MANAGEMENT, LLC

Latest 13F report
Q2 2018 - 13 Aug 2018
Value $
$0
Signature - Title
Jacob Carmona - Chief Financial Officer and Director of Operations
Location
New York, NY
Summary
This page shows a list of all the recent 13F filings made by SENZAR ASSET MANAGEMENT, LLC. Form 13F is required to be filed within 45 days of the end of a calendar quarter. SENZAR ASSET MANAGEMENT, LLC reported 24 stock holdings with total value $34,657,000 as of Q2 2018. Top holdings included MRK, SNY, MYL, CI, and AZN.

Notify me when SENZAR ASSET MANAGEMENT, LLC files a new 13F portfolio report.

⭐ Subscribe ⭐
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q3 2018 0 $0 $0 -$34,657,000 -$34,657,000 13F-HR 31 Oct 2018, 11:15
Q2 2018 24 $34,657,000 +$5,486,000 -$266,904,312 -$261,418,312 MRK, SNY, MYL, CI, AZN 13F-HR 13 Aug 2018, 16:43
Q1 2018 30 $295,085,000 +$127,160,141 -$206,117,947 -$78,957,806 AZN, REGN, SNY, MYL, AGN 13F-HR 14 May 2018, 16:29
Q4 2017 29 $390,543,000 +$230,496,283 -$225,351,288 +$5,144,995 SNY, REGN, MYL, AET, CVS 13F-HR 13 Feb 2018, 16:28
Q3 2017 27 $382,681,000 +$239,145,607 -$287,178,153 -$48,032,546 HALO, SNY, REGN, AGNPRA, TSRO 13F-HR 13 Nov 2017, 16:17
Q2 2017 23 $406,153,000 +$189,714,922 -$183,786,124 +$5,928,798 HALO, ESRX, MYL, NBIX, LLY 13F-HR 11 Aug 2017, 16:39
Q1 2017 28 $394,697,000 +$190,742,289 -$186,237,427 +$4,504,862 SNY, HALO, ESRX, ELV, GILD 13F-HR 12 May 2017, 16:19
Q4 2016 30 $377,077,000 +$126,519,569 -$132,205,820 -$5,686,251 SNY, LLY, SHPG, AGN, ELV 13F-HR 13 Feb 2017, 17:33
Q3 2016 35 $386,779,122 +$117,501,946 -$211,620,865 -$94,118,919 SNY, LLY, ELV, SHPG, ESRX 13F-HR 14 Nov 2016, 16:38
Q2 2016 41 $458,954,695 +$233,602,958 -$287,028,576 -$53,425,618 LLY, SNY, ABT, SHPG, BIIB 13F-HR 12 Aug 2016, 16:09
Q1 2016 37 $503,667,574 +$148,063,645 -$428,232,221 -$280,168,576 NVRO, AMGN, AGN, TEVA, ELV 13F-HR 13 May 2016, 16:28
Q4 2015 41 $899,397,305 +$314,756,952 -$212,841,013 +$101,915,939 VRX, NVRO, TEVA, AET, MYL 13F-HR 12 Feb 2016, 16:09
Q3 2015 36 $687,471,839 +$406,511,095 -$253,274,705 +$153,236,390 NVRO, MYL, TEVA, STJ, AET 13F-HR 16 Nov 2015, 16:32
Q2 2015 38 $582,357,000 +$294,539,716 -$137,852,321 +$156,687,395 NVRO, TEVA, LH, STJ, PRGO 13F-HR 14 Aug 2015, 16:07
Q1 2015 33 $410,334,000 +$259,896,782 -$211,315,148 +$48,581,634 STJ, KND, TEVA, NVRO, SNY 13F-HR 15 May 2015, 09:54
Q4 2014 32 $341,188,000 +$143,768,197 -$174,618,542 -$30,850,345 SNY, MYL, CYH, VRX, B108PS 13F-HR 17 Feb 2015, 16:41
Q3 2014 29 $341,028,000 +$151,317,709 -$61,804,698 +$89,513,011 MYL, GSK, TEVA, SNY, F113PS 13F-HR 14 Nov 2014, 13:49
Q2 2014 26 $261,810,000 +$91,711,552 -$35,139,946 +$56,571,606 TEVA, SNY, CYH, ABBV, INSM 13F-HR 14 Aug 2014, 16:05
Q1 2014 18 $188,833,000 +$103,152,554 -$48,263,566 +$54,888,988 ABBV, SNY, TEVA, MDVN, AMGN 13F-HR 15 May 2014, 16:09
Q4 2013 19 $122,403,000 $0 $0 $0 GSK, TEVA, MYL, CYH, OFIX 13F-HR 14 Feb 2014, 10:38